Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BCMA-CD3 Bispecific”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05137054
What this trial is testing

Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Who this might be right for
Multiple Myeloma
Regeneron Pharmaceuticals 317
Testing effectiveness (Phase 2)Looking for participantsNCT05972135
What this trial is testing

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 100
Testing effectiveness (Phase 2)Looking for participantsNCT07455851
What this trial is testing

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 150
Testing effectiveness (Phase 2)Study completedNCT04083534
What this trial is testing

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Regeneron Pharmaceuticals 43
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07695740
What this trial is testing

Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Excyte Biopharma Ltd 64
Not applicableStudy completedNCT06504524
What this trial is testing

Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Who this might be right for
Multiple Myeloma
Pfizer 633
Not applicableStudy completedNCT05932290
What this trial is testing

Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 514
Testing effectiveness (Phase 2)Looking for participantsNCT06900010
What this trial is testing

Evaluate CM336 in Adults With Autoimmune Bullous Disease

Who this might be right for
Autoimmune Bullous Disease
Shandong First Medical University 30
Testing effectiveness (Phase 2)Looking for participantsNCT07585760
What this trial is testing

CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment

Who this might be right for
Multiple Myeloma (MM)Multiple Myeloma Light Chain Induced Renal Insufficiency
Institute of Hematology & Blood Diseases Hospital, China 26
Not applicableStudy completedNCT05565391
What this trial is testing

Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 508
Testing effectiveness (Phase 2)Looking for participantsNCT07115667
What this trial is testing

Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration

Who this might be right for
Solitary Bone PlasmacytomaPlasmacytoma of BonePlasma Cell Disorders
Institute of Hematology & Blood Diseases Hospital, China 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07789522
What this trial is testing

Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT04649359
What this trial is testing

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Who this might be right for
Multiple Myeloma
Pfizer 187
Large-scale testing (Phase 3)Looking for participantsNCT06932562
What this trial is testing

Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 1,000
Early research (Phase 1)Active Not RecruitingNCT03145181
What this trial is testing

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 302
Testing effectiveness (Phase 2)Looking for participantsNCT05828511
What this trial is testing

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Who this might be right for
Multiple Myeloma
Regeneron Pharmaceuticals 149
Testing effectiveness (Phase 2)Ended earlyNCT04735575
What this trial is testing

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Shanghai EpimAb Biotherapeutics Co., Ltd. 40
Testing effectiveness (Phase 2)Study completedNCT04696809
What this trial is testing

Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematologic Malignancies
Janssen Pharmaceutical K.K. 40
Testing effectiveness (Phase 2)Looking for participantsNCT07151690
What this trial is testing

BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

Who this might be right for
Systemic Light Chain Amyloidosis
Institute of Hematology & Blood Diseases Hospital, China 21
Very early researchNot Yet RecruitingNCT07185477
What this trial is testing

A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 20
Next Page